Revvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestiture
ORIGINAL SOURCE →via Seeking Alpha
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [ENERGY] China’s Big Bet on Wind Power Is Paying Off
- [ENERGY] China’s Big Bet on Wind Power Is Paying Off. As Trump's war in Iran threatens to choke off oil and gas supplies from the Persian Gulf, China is seizing the moment to extend its dominance in wind power. The war has made China’s investments in wind look prescient. The contrast with the US is stark.
- [CONFLICT] I’m Leaving China After 8 Years. Suspicion of Outsiders Is Rising.
- [CONFLICT] Legacy Automakers Pivot On Their Legacies At Auto China
- [CONFLICT] Francia incita al G7 a hacer frente al "casi monopolio de China" con las tierras raras